Recording: Paradigm shifts in metastatic hormone sensitive prostate cancer (mHSPC): Recent treatment developments
This recording examines the most recent developments in the treatment of hormone-sensitive prostate cancer. It follows on from “Management of Non-metastatic Castration Resistant Prostate Cancer (nmCRPC): Putting current evidence into practice” held in April. In three talks, we will examine the role of treatment intensification, radioligand therapy and the personalized approach in mHSPC. The webinar will take approximately one hour and includes the possibility to ask questions during the Q&A.
| Organiser | European School of Urology (ESU) |
|---|---|
| CME | Not approved |
| Duration | Approx. 60 minutes |
In this recording we will address the following questions:
- Is PSMA-PET scan the preferred imaging modality in mHSPC or are bone and CT scans sufficient?
- What is the best treatment for men with mHSPC?
- Is it the combination treatment of androgen deprivation therapy (ADT) plus docetaxel or an androgen receptor signaling inhibitor (ARSi) or triplet therapy?
- Are any of these combination treatments for high-volume disease only?
- What is the indication for adding radiotherapy?
- Is there a difference between treatment for de novo disease or recurrent disease after treatment of the primary tumour?